Abstract:Parkinson's disease (PD) is now recognized as a neurodegenerative condition caused by a complex interplay of genetic and environmental influences. Chronic manganese (Mn) exposure has been implicated in the development of PD. Since mitochondrial dysfunction is associated with PD pathology as well as Mn neurotoxicity, we investigated whether Mn exposure augments mitochondrial dysfunction and neurodegeneration in the nigrostriatal dopaminergic system using a newly available mitochondrially defective transgenic mouse model of PD, the MitoPark mouse. This unique PD model recapitulates key features of the disease including progressive neurobehavioral changes and neuronal degeneration. We exposed MitoPark mice to a low dose of Mn (10mg/kg, p.o.) daily for 4 weeks starting at age 8 wks and then determined the behavioral, neurochemical and histological changes. Mn exposure accelerated the rate of progression of motor deficits in MitoPark mice when compared to the untreated MitoPark group. Mn also worsened olfactory function in this model. Most importantly, Mn exposure intensified the depletion of striatal dopamine and nigral TH neuronal loss in MitoPark mice. The neurodegenerative changes were accompanied by enhanced oxidative damage in the striatum and substantia nigra (SN) of MitoPark mice treated with Mn. Furthermore, Mn-treated MitoPark mice had significantly more oligomeric protein and IBA-1-immunoreactive microglia cells, suggesting Mn augments neuroinflammatory processes in the nigrostriatal pathway. To further confirm the direct effect of Mn on impaired mitochondrial function, we also generated a mitochondrially defective dopaminergic cell model by knocking out the TFAM transcription factor by using a CRISPR-Cas9 gene-editing method. Seahorse mitochondrial bioenergetic analysis revealed that Mn decreases mitochondrial basal and ATP-linked respiration in the TFAM KO cells. Collectively, our results reveal that Mn can augment mitochondrial dysfunction to exacerbate nigrostriatal neurodegeneration and PD-related behavioral symptoms. Our study also demonstrates that the MitoPark mouse is an excellent model to study the gene-environment interactions associated with mitochondrial defects in the nigral dopaminergic system as well as to evaluate the contribution of potential environmental toxicant interactions in a slowly progressive model of Parkinsonism.

Manganese Intoxication Recovery and the Expression Changes of Park2/Parkin in Rats

Manganese overexposure induces Parkinson-like symptoms, altered lipid signature and oxidative stress in C57BL/6 J mouse

Chronic Manganese Administration with Longer Intervals Between Injections Produced Neurotoxicity and Hepatotoxicity in Rats.

Manganese Exposure Causes Movement Deficit and Changes in the Protein Profile of the External Globus Pallidus in Sprague Dawley Rats.

Manganese Causes Neurotoxic Iron Accumulation Via Translational Repression of Amyloid Precursor Protein and H‐Ferritin

The tolerable upper intake level of manganese alleviates Parkinson-like motor performance and neuronal loss by activating mitophagy

[The Comparison of Neurobehavioral Changes and Impaired Locations Between the Mouse Model of Manganism and Parkinson's Disease].

Manganese exposure leads to depressive-like behavior through disruption of the Gln-Glu-GABA metabolic cycle

Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity

Manganese exposure leads to depressive-like behavior through disruption of the GlnGluGABA metabolic cycle

Manganese induces oxidative damage in the hippocampus by regulating the expression of oxidative stress‐related genes via modulation of H3K18 acetylation

Manganese Induces Dopaminergic Neurodegeneration Via Microglial Activation in a Rat Model of Manganism.

Manganese Induces Neuroinflammation Via NF-κB/ROS NLRP3 Pathway in Rat Brain Striatum and HAPI Cells

Intrastriatal Manganese Chloride Exposure Causes Acute Locomotor Impairment As Well As Partial Activation of Substantia Nigra GABAergic Neurons

Manganese-Induced Parkinsonism and Parkinson’s Disease: Shared and Distinguishable Features

Subchronic, Low-Level Intraperitoneal Injections of Manganese (IV) Oxide and Manganese (II) Chloride Affect Rat Brain Neurochemistry

Manganese Injection into the Rat Striatum Produces Excitotoxic Lesions by Impairing Energy Metabolism

Manganese-Induced Parkinsonism: Evidence from Epidemiological and Experimental Studies

Manganese and Parkinson’s Disease: A Critical Review and New Findings

Dopaminergic REST/NRSF is protective against manganese-induced neurotoxicity in mice